articleThe Lancet Respiratory MedicineApr 14, 2025GREEN OA

Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial

MGMichael G. IsonAPAlberto PapiEAEugene AthanRGRobert G. FeldmanJMJoanne M. Langley

Dalhousie University · Nova Scotia Health Authority · +7 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

46
total citations
FWCI
48.61
Percentile
100%
References
21
Citations per year

Authors

150

Topics & keywords

Topics
Keywords
  • Medicine
  • Immunogenicity
  • Respiratory system
  • Virus
  • Virology
  • Immunology
  • Internal medicine
  • Antibody
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding